AR035227A1 - Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus - Google Patents
Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirusInfo
- Publication number
- AR035227A1 AR035227A1 ARP020100466A ARP020100466A AR035227A1 AR 035227 A1 AR035227 A1 AR 035227A1 AR P020100466 A ARP020100466 A AR P020100466A AR P020100466 A ARP020100466 A AR P020100466A AR 035227 A1 AR035227 A1 AR 035227A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- reovirus
- chemotherapeutic agent
- effective amount
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de un agente quimioterapéutico, que comprende: (a) una cantidad efectiva de un reovirus; y (b) una cantidad efectiva del agente quimioterapéutico a dicha célula, que es para la manufactura de un medicamento para la sensibilización de una célula neoplásica. Reivindicación 6: El método de la reivindicación 1, en la cual el agente quimioterapéutico se selecciona del grupo que consiste en 5-fluorouracilo, mitomicin C, metotrexate, hidroxiurea, ciclofosfamide, dacarbazine, mitoxantrone, antraciclinas, carboplatino, cisplatino, taxol, taxotere, tamoxifen, anti-estrógenos e interferones. Reivindicación 11: El método de la reivindicación 10, en el cual el reovirus serotipo 3 es un reovirus de cepa Dearing. Reivindicación 12: Un método para tratar un sujeto que alberga un desorden proliferativo, en el cual dicho sujeto comprende células neoplásicas que son refractarias a un agente quimioterapéutico, que comprende: (a) administrar al sujeto una cantidad efectiva de reovirus en condiciones que den como resultado una infección de las células neoplásicas por el reovirus; y (b) administrar una cantidad efectiva del agente quimioterapéutico a dicho sujeto. Reivindicación 19: El método de la reivindicación 12, en el cual el desorden proliferativo es un tumor sólido. Reivindicación 20: El método de la reivindicación 19, en el cual el tumor sólido se selecciona del grupo que consiste en cáncer pulmonar, cáncer de próstata, cáncer colorectal, cáncer de tiroides, cáncer renal, cáncer adrenal, cáncer de hígado, cáncer pancreático, cáncer de mama y cáncer del sistema nervioso central y periférico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27036301P | 2001-02-20 | 2001-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035227A1 true AR035227A1 (es) | 2004-05-05 |
Family
ID=23031034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100466A AR035227A1 (es) | 2001-02-20 | 2002-02-12 | Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US7264798B2 (es) |
| EP (2) | EP1361884B1 (es) |
| JP (3) | JP4951194B2 (es) |
| AR (1) | AR035227A1 (es) |
| AT (1) | ATE516807T1 (es) |
| AU (2) | AU2002234453B2 (es) |
| BR (1) | BR0207691A (es) |
| CA (1) | CA2437468C (es) |
| DK (1) | DK1361884T3 (es) |
| ES (1) | ES2367768T3 (es) |
| HK (1) | HK1060520A1 (es) |
| IL (2) | IL157167A0 (es) |
| MX (1) | MXPA03007486A (es) |
| NZ (2) | NZ537709A (es) |
| WO (1) | WO2002066040A2 (es) |
| ZA (1) | ZA200305875B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| AR035227A1 (es) | 2001-02-20 | 2004-05-05 | Oncolytics Biotech Inc | Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus |
| WO2003094939A1 (en) * | 2002-05-10 | 2003-11-20 | Oncolytics Biotech Inc. | Sensitization of neoplastic cells to radiation therapy with oncolytic viruses |
| CA2522711A1 (en) * | 2003-04-25 | 2004-11-11 | Wellstat Biologics Corporation | Treating hepatocellular carcinomas using therapeutic viruses |
| DE602004018927D1 (de) | 2003-06-18 | 2009-02-26 | Genelux Corp | Modifizierte rekombinante vacciniaviren, verwendungen davon |
| CN1946421B (zh) * | 2004-04-27 | 2013-07-17 | 威尔斯达特生物制剂公司 | 使用病毒和喜树碱进行的癌症治疗 |
| WO2005112966A1 (en) * | 2004-05-21 | 2005-12-01 | Orison Biotechnology Inc. | Combined therapy with a herbal extract and a reovirus for killing neoplastic cells in a subject |
| RU2435586C2 (ru) * | 2005-07-14 | 2011-12-10 | Веллстат Байолоджикс Корпорейшн | Лечение рака с применением вирусов, фторпиримидинов и камптотецинов |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| WO2007099401A2 (en) * | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Oncolytic attenuated reoviruses for treatment of proliferative disorders |
| DE602006010902D1 (de) * | 2005-11-24 | 2010-01-14 | Aicuris Gmbh & Co Kg | Parapocken-viren in kombination mit klassischen zytotoxischen chemotherapeutika als biochemotherapie zur behandlung von krebs |
| US8052968B2 (en) | 2006-10-16 | 2011-11-08 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
| WO2008150496A2 (en) * | 2007-05-31 | 2008-12-11 | Genelux Corporation | Assay for sensitivity to chemotherapeutic agents |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| JP2010533718A (ja) * | 2007-07-18 | 2010-10-28 | ジェネラックス・コーポレイション | 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用 |
| JP2011500608A (ja) * | 2007-10-22 | 2011-01-06 | オンコリティクス バイオテク，インコーポレーテッド | 増殖性障害の治療レジメン |
| AU2009210654A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Use of picoplatin and bevacizumab to treat colorectal cancer |
| EP2300023A2 (en) * | 2008-05-16 | 2011-03-30 | Genelux Corporation | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| KR101585702B1 (ko) * | 2008-05-22 | 2016-01-15 | 제일약품주식회사 | 종양파괴 바이러스 요법에 대한 과다증식성 세포의 종양 억제인자-기초된 민감성 |
| JP2011520994A (ja) * | 2008-05-27 | 2011-07-21 | オンコリティクス バイオテク，インコーポレーテッド | 腫瘍崩解性レオウイルス療法中の炎症性サイトカイン産生の排除 |
| TW200951143A (en) * | 2008-05-27 | 2009-12-16 | Oncolytics Biotech Inc | Modulating interstitial pressure and oncolytic viral delivery and distribution |
| WO2013163724A1 (en) * | 2012-04-30 | 2013-11-07 | Oncolytics Biotech Inc. | Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein |
| EP3209382B1 (en) | 2014-10-24 | 2020-11-25 | Calidi Biotherapeutics, Inc. | Combination immunotherapy approach for treatment of cancer |
| CN104881181B (zh) * | 2015-05-27 | 2019-07-26 | 联想(北京)有限公司 | 显示方法及电子设备 |
| EP3876951A1 (en) | 2018-11-06 | 2021-09-15 | Calidi Biotherapeutics, Inc. | Enhanced systems for cell-mediated oncolytic viral therapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU682854B2 (en) | 1993-02-16 | 1997-10-23 | Onyx Pharmaceuticals | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| DK1314431T3 (da) | 1993-04-30 | 2008-11-10 | Wellstat Biologics Corp | Oprensede sammensætninger af Newcastle disease virus |
| US5776743A (en) | 1994-09-06 | 1998-07-07 | La Jolla Cancer Research Foundation | Method of sensitizing tumor cells with adenovirus E1A |
| US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US6565831B1 (en) * | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| US6136307A (en) | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| NZ518945A (en) | 1997-10-09 | 2007-03-30 | Wellstat Biologics Corp | Treatment of neoplasms with viruses |
| US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| AU782020B2 (en) * | 1999-11-12 | 2005-06-30 | Oncolytics Biotech, Inc. | Viruses for the treatment of cellular proliferative disorders |
| AR035227A1 (es) * | 2001-02-20 | 2004-05-05 | Oncolytics Biotech Inc | Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus |
| US7163678B2 (en) * | 2002-11-07 | 2007-01-16 | Oncolytics Biotech Inc. | Reovirus for the treatment of ral-mediated cellular proliferative disorders |
-
2002
- 2002-02-12 AR ARP020100466A patent/AR035227A1/es unknown
- 2002-02-15 US US10/076,074 patent/US7264798B2/en not_active Expired - Lifetime
- 2002-02-19 CA CA002437468A patent/CA2437468C/en not_active Expired - Lifetime
- 2002-02-19 BR BR0207691-8A patent/BR0207691A/pt not_active IP Right Cessation
- 2002-02-19 DK DK02701122.0T patent/DK1361884T3/da active
- 2002-02-19 EP EP02701122A patent/EP1361884B1/en not_active Expired - Lifetime
- 2002-02-19 EP EP10013901A patent/EP2314301A3/en not_active Withdrawn
- 2002-02-19 NZ NZ537709A patent/NZ537709A/en unknown
- 2002-02-19 JP JP2002565598A patent/JP4951194B2/ja not_active Expired - Lifetime
- 2002-02-19 NZ NZ527399A patent/NZ527399A/en unknown
- 2002-02-19 IL IL15716702A patent/IL157167A0/xx unknown
- 2002-02-19 WO PCT/CA2002/000201 patent/WO2002066040A2/en active IP Right Grant
- 2002-02-19 AT AT02701122T patent/ATE516807T1/de not_active IP Right Cessation
- 2002-02-19 MX MXPA03007486A patent/MXPA03007486A/es active IP Right Grant
- 2002-02-19 AU AU2002234453A patent/AU2002234453B2/en not_active Expired
- 2002-02-19 ES ES02701122T patent/ES2367768T3/es not_active Expired - Lifetime
-
2003
- 2003-07-30 IL IL157167A patent/IL157167A/en active IP Right Grant
- 2003-07-30 ZA ZA200305875A patent/ZA200305875B/en unknown
-
2004
- 2004-05-19 HK HK04103556.6A patent/HK1060520A1/xx not_active IP Right Cessation
-
2007
- 2007-05-31 US US11/809,293 patent/US7608257B2/en not_active Expired - Lifetime
- 2007-08-16 AU AU2007207860A patent/AU2007207860B2/en not_active Expired
-
2008
- 2008-02-18 JP JP2008036723A patent/JP2008120837A/ja not_active Withdrawn
-
2009
- 2009-09-08 US US12/555,453 patent/US7964187B2/en not_active Expired - Fee Related
-
2011
- 2011-05-17 US US13/109,631 patent/US20110243890A1/en not_active Abandoned
-
2012
- 2012-01-13 JP JP2012005027A patent/JP2012072192A/ja active Pending
- 2012-09-24 US US13/625,259 patent/US8658158B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035227A1 (es) | Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus | |
| Zhang et al. | A programmable polymer library that enables the construction of stimuli-responsive nanocarriers containing logic gates | |
| Timaner et al. | Therapy-educated mesenchymal stem cells enrich for tumor-initiating cells | |
| Fischer et al. | Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance | |
| Recchia et al. | Gonadotropin‐releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma | |
| Milas et al. | Chemoradiotherapy: emerging treatment improvement strategies | |
| JP2004517966A5 (es) | ||
| Shukla et al. | Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer | |
| Lu et al. | Drug delivery using nanoparticles for cancer stem-like cell targeting | |
| Tekedereli et al. | Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (−) and ER (+) breast cancer | |
| Li et al. | Locoregional therapy with α‐emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2‐positive gastric cancer in mice | |
| Lam et al. | Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma | |
| Crowder et al. | Cancer stem cells under hypoxia as a chemoresistance factor in the breast and brain | |
| Wei et al. | Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor κB | |
| Schein et al. | Phase I Clinical Trial of Spirogermanium¹ | |
| Joensuu et al. | A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer | |
| Lin et al. | Nanomedicine targets iron metabolism for cancer therapy | |
| Krishnamurthy et al. | Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells | |
| Hack et al. | Platinum-based chemotherapy ‘rechallenge’in advanced non-ovarian solid malignancies | |
| US6342520B1 (en) | Locally injectable chemotherapeutics | |
| Chen et al. | Radiation therapy concurrent with weekly paclitaxel for locoregionally advanced nasopharyngeal carcinoma: outcomes of a phase I trial | |
| CN1787814A (zh) | 增加抗癌药剂抗肿瘤活性的方法 | |
| Pavel et al. | Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors | |
| Abe et al. | Some aspects of size-dependent differential drug response in primary and metastatic tumors | |
| Oon et al. | Adriamycin in the treatment of resectible and irresectible primary hepatocellular carcinoma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |